Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Stage I Prostate Adenocarcinoma AJCC v7 1Prostatic Neoplasms 1Prostate Adenocarcinoma 1

Interventions

relugolix 2luprolide acetate gel depot 2acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2Specimen Handling 2Radiotherapy 2Radiation 2Magnetic Resonance Spectroscopy 2Leuprolide 2Goserelin 2Biopsy 2radium Ra 223 dichloride 1histrelin 1gallium 68 PSMA-11 1enzalutamide 1darolutamide 1bicalutamide 1Triptorelin Pamoate 1Surgical Procedures, Operative 1Salicylic Acid 1Radiotherapy, Image-Guided 1Radiosurgery 1Radiation Dose Hypofractionation 1Flutamide 1Buserelin 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostate Adenocarcinoma × Salicylic Acid × 90 days × Clear all
NCT05050084 2026-05-04

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

NRG Oncology

Phase 3 Active not recruiting
2,050 enrolled
Genitourinary

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡